Sotatercept for the Treatment of Pulmonary Arterial Hypertension
Clinical Trial | By M Humbert, V McLaughlin, PULSAR Trial Investigators et al.
BACKGROUND - Pulmonary arterial hypertension is characterized by pulmonary vascular remodeling, cellular proliferation, and poor long-term outcomes. Dysfunctional bone morphogenetic protein pathway signaling is associated with both hereditary and idiopathic subtypes. Sotatercept, a novel fusion protein, binds activins and growth differentiation factors in the attempt to restore balance between growth-promoting and growt...
Original Research | By S Baratchi, MTK Zaldivia, M Wallert et al.
Clinical Trial | By DC Wheeler, BV Stefánsson, DAPA-CKD Trial Committees and Investigators et al.
BACKGROUND - Dapagliflozin reduces the risk of kidney failure and heart failure in patients with chronic kidney disease. We aimed to investigate the effects of dapagliflozin on kidney, cardiovascular, and mortality outcomes according to presence or absence of type 2 diabetes and according to underlying cause of chronic kidney disease, reported as diabetic nephropathy, chronic glomerulonephritides, ischaemic or hypertensive chronic kidney disease, or...
Cardiac monocytes and macrophages after myocardial infarction
Clinical Trial | By L Kuo , DS Frankel, S Nazarian et al.
BACKGROUND - We have previously shown that the presence of dual muscular coronary sinus (CS) to left atrial (LA) connections, coupled with rate-dependent unidirectional block in one limb, is associated with atrial fibrillation (AF) induction. This study sought to examine whether ablation of distal CS to LA connections at a first AF ablation reduces arrhythmia recurrence during follow-up. METHODS&n...
Reduced Apolipoprotein M and Adverse Outcomes Across the Spectrum of Human Heart Failure
SR-B1 Drives Endothelial Cell LDL Transcytosis via DOCK4 to Promote Atherosclerosis
Original Research | By LZ Huang, KL Chambliss, PW Shaul et al.